CL2013000100A1 - Composicion que comprende un agente de contraste para rayos x yodado y un portador o excipiente farmaceuticamente aceptable, donde la concentracion de yodo es de 10-170 mgl/ml; un metodo de examen con rayos x que comprende el uso de la composicion. - Google Patents

Composicion que comprende un agente de contraste para rayos x yodado y un portador o excipiente farmaceuticamente aceptable, donde la concentracion de yodo es de 10-170 mgl/ml; un metodo de examen con rayos x que comprende el uso de la composicion.

Info

Publication number
CL2013000100A1
CL2013000100A1 CL2013000100A CL2013000100A CL2013000100A1 CL 2013000100 A1 CL2013000100 A1 CL 2013000100A1 CL 2013000100 A CL2013000100 A CL 2013000100A CL 2013000100 A CL2013000100 A CL 2013000100A CL 2013000100 A1 CL2013000100 A1 CL 2013000100A1
Authority
CL
Chile
Prior art keywords
composition
ray
mgl
iodinated
excipient
Prior art date
Application number
CL2013000100A
Other languages
English (en)
Inventor
Clemens Kaiser
Ben Newton
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000100(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of CL2013000100A1 publication Critical patent/CL2013000100A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A61B6/035—Mechanical aspects of CT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/40—Arrangements for generating radiation specially adapted for radiation diagnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/48—Diagnostic techniques
    • A61B6/481—Diagnostic techniques involving the use of contrast agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
    • A61B6/5258—Devices using data or image processing specially adapted for radiation diagnosis involving detection or reduction of artifacts or noise
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/007—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests for contrast media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Theoretical Computer Science (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus For Radiation Diagnosis (AREA)

Abstract

Composición que comprende un agente de contraste para rayos X yodado y un portador o excipiente farmacéuticamente aceptable, donde la concentración de yodo es de 10-170 mgl/ml; un método de exámen con rayos X que comprende el uso de la composición.
CL2013000100A 2010-07-12 2013-01-10 Composicion que comprende un agente de contraste para rayos x yodado y un portador o excipiente farmaceuticamente aceptable, donde la concentracion de yodo es de 10-170 mgl/ml; un metodo de examen con rayos x que comprende el uso de la composicion. CL2013000100A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NO20101001 2010-07-12
US41678810P 2010-11-24 2010-11-24
NO20101660 2010-11-26
NO20110499 2011-03-31

Publications (1)

Publication Number Publication Date
CL2013000100A1 true CL2013000100A1 (es) 2013-07-19

Family

ID=44532477

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000100A CL2013000100A1 (es) 2010-07-12 2013-01-10 Composicion que comprende un agente de contraste para rayos x yodado y un portador o excipiente farmaceuticamente aceptable, donde la concentracion de yodo es de 10-170 mgl/ml; un metodo de examen con rayos x que comprende el uso de la composicion.

Country Status (16)

Country Link
US (1) US20130116554A1 (es)
EP (1) EP2593143A1 (es)
JP (2) JP2013531685A (es)
KR (1) KR101585751B1 (es)
CN (2) CN102985114A (es)
AU (1) AU2011278377B2 (es)
BR (1) BR112012033776A2 (es)
CA (1) CA2801828A1 (es)
CL (1) CL2013000100A1 (es)
IL (1) IL223469A (es)
MX (1) MX2013000476A (es)
NZ (1) NZ605674A (es)
RU (1) RU2566281C2 (es)
SG (1) SG186905A1 (es)
TN (1) TN2012000621A1 (es)
WO (1) WO2012007456A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150250902A1 (en) * 2008-08-22 2015-09-10 Colorado School Of Mines pH-RESPONSIVE GADOLINIUM NANOPARTICLE CONJUGATES AND USES THEREOF
US8968705B2 (en) 2008-08-22 2015-03-03 Colorado School Of Mines Gold/lanthanide nanoparticle conjugates and uses thereof
WO2013104690A1 (en) * 2012-01-11 2013-07-18 Ge Healthcare As X-ray imaging contrast media with low iodine concentration and x-ray imaging process
RU2014138059A (ru) * 2012-02-21 2016-04-10 Конинклейке Филипс Н.В. Адаптивная радиотерапия со спектральной визуализацией и отслеживанием интересующей ткани
US9271688B2 (en) * 2012-03-28 2016-03-01 General Electric Company System and method for contrast agent estimation in X-ray imaging
US9332953B2 (en) * 2012-08-31 2016-05-10 The University Of Chicago Supervised machine learning technique for reduction of radiation dose in computed tomography imaging
AU2013323982B2 (en) * 2012-09-27 2017-11-23 Ge Healthcare As Preparation of Ioforminol, an X-ray contrast agent
MX2015013658A (es) * 2013-03-27 2016-02-18 Ge Healthcare As Metodo y reactivo para preparar una composicion diagnostica.
WO2014167463A2 (en) * 2013-04-10 2014-10-16 Koninklijke Philips N.V. Image quality index and/or imaging parameter recommendation based thereon
US9836862B2 (en) 2014-12-30 2017-12-05 General Electric Company Methods and systems for contrast enhanced imaging with single energy acquisition
CN107773242B (zh) * 2016-08-31 2023-05-12 通用电气公司 磁共振成像方法及系统
BR112020007105A2 (pt) * 2017-10-09 2020-09-24 The Board Of Trustees Of The Leland Stanford Junior University método para treinar um dispositivo de diagnóstico por imagem para realizar uma imagem para diagnóstico médico com uma dose reduzida de agente de contraste
US11497459B2 (en) * 2018-01-26 2022-11-15 General Electric Company Methods and system for optimizing an imaging scan based on a prior scan
JP7144987B2 (ja) * 2018-06-27 2022-09-30 キヤノン株式会社 放射線撮影装置、放射線撮影方法およびプログラム
WO2020003744A1 (ja) 2018-06-27 2020-01-02 キヤノン株式会社 放射線撮影装置、放射線撮影方法およびプログラム
JP7144988B2 (ja) * 2018-06-27 2022-09-30 キヤノン株式会社 放射線撮影装置、放射線撮影方法およびプログラム
WO2020163629A1 (en) 2019-02-06 2020-08-13 Butler William E Spatiotemporal reconstruction of a moving vascular pulse wave from a plurality of lower dimensional angiographic projections
CN113423438A (zh) * 2019-02-06 2021-09-21 威廉·E·巴特勒 用于血管造影的改进方法
WO2020198592A1 (en) 2019-03-27 2020-10-01 Butler William E Reconstructing cardiac frequency phenomena in angiographic data
US11030742B2 (en) * 2019-03-29 2021-06-08 GE Precision Healthcare LLC Systems and methods to facilitate review of liver tumor cases
AU2020252576B2 (en) 2019-04-04 2023-05-18 William E. Butler Intrinsic contrast optical cross-correlated wavelet angiography
US11096642B2 (en) * 2019-08-16 2021-08-24 GE Precision Healthcare LLC Methods and systems for X-ray tube conditioning
CN112581554B (zh) * 2019-09-30 2024-02-27 中国科学院深圳先进技术研究院 一种ct成像方法、装置、存储设备及医学成像系统
US11288775B2 (en) * 2019-11-27 2022-03-29 GE Precision Healthcare LLC Methods and systems for parametric noise modulation in x-ray imaging
CN111494652B (zh) * 2020-05-19 2022-03-22 复旦大学附属眼耳鼻喉科医院 一种基于双能量ct成像对肿瘤进行检测的酸环境响应对比剂及其制备方法和应用
US20230368352A1 (en) * 2022-05-16 2023-11-16 Varian Medical Systems, Inc. System and methods for quantification of substance concentration in body structures using spectral computed tomography

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548594A (en) * 1976-06-11 1979-07-18 Nyegaard & Co As Triiodoisophthalic acid amides
NO161368C (no) 1982-11-08 1989-08-09 Nyegaard & Co As Roentgenkontrastmidler samt radiologiske preparater derav.
US4887604A (en) * 1988-05-16 1989-12-19 Science Research Laboratory, Inc. Apparatus for performing dual energy medical imaging
GB8916781D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions
US5443814A (en) * 1992-05-01 1995-08-22 Sterling Winthrop, Inc. X-ray contrast compositions containing iodophenoxyalkanes and cellulose derivatives
DE4344464A1 (de) * 1993-12-22 1995-06-29 Schering Ag Kaskadenpolymere mit Iodaromaten
US6818199B1 (en) * 1994-07-29 2004-11-16 James F. Hainfeld Media and methods for enhanced medical imaging
US6333971B2 (en) * 1995-06-07 2001-12-25 George S. Allen Fiducial marker
EP0855997A4 (en) 1995-06-16 1998-10-07 Biophysica Inc FORMYL DERIVATIVES AS NON-IONIC CONTRAST AGENTS
IL129609A0 (en) * 1996-11-01 2000-02-29 Miley George H Spherical inertial electrostatic confinement device as a tunable x-ray source
US7713517B2 (en) * 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US7486984B2 (en) * 2004-05-19 2009-02-03 Mxisystems, Inc. System and method for monochromatic x-ray beam therapy
DE102005052368B4 (de) * 2005-10-31 2015-07-30 Bayer Pharma Aktiengesellschaft Röntgensystem zur Erstellung diagnostischer Röntgendarstellungen unter Applikation von Kontrastmitteln
US8920780B2 (en) * 2007-07-12 2014-12-30 Ge Healthcare As Contrast agents
EP2385845A1 (en) 2009-01-09 2011-11-16 Ge Healthcare As Contrast media compositions

Also Published As

Publication number Publication date
MX2013000476A (es) 2013-02-11
RU2566281C2 (ru) 2015-10-20
CN102985114A (zh) 2013-03-20
JP2016193921A (ja) 2016-11-17
NZ605674A (en) 2014-11-28
TN2012000621A1 (en) 2014-04-01
CN105194692A (zh) 2015-12-30
WO2012007456A1 (en) 2012-01-19
RU2012155122A (ru) 2014-08-20
KR101585751B1 (ko) 2016-01-14
AU2011278377B2 (en) 2014-08-14
AU2011278377A1 (en) 2013-02-21
US20130116554A1 (en) 2013-05-09
EP2593143A1 (en) 2013-05-22
IL223469A (en) 2015-10-29
JP2013531685A (ja) 2013-08-08
SG186905A1 (en) 2013-02-28
KR20130116237A (ko) 2013-10-23
CA2801828A1 (en) 2012-01-19
BR112012033776A2 (pt) 2016-11-01

Similar Documents

Publication Publication Date Title
CL2013000100A1 (es) Composicion que comprende un agente de contraste para rayos x yodado y un portador o excipiente farmaceuticamente aceptable, donde la concentracion de yodo es de 10-170 mgl/ml; un metodo de examen con rayos x que comprende el uso de la composicion.
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
BRPI0618577A8 (pt) Usos de rituximab
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
CL2011000527A1 (es) Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
CY1123240T1 (el) Αντισωμα αντι fgf23 και μια φαρμακευτικη συνθεση που το περιλαμβανει
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BRPI0513812B8 (pt) método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
BR112015023520A2 (pt) purificação do conjugado de anticorpo-fármaco (adc)
BR112012022797A2 (pt) composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool
CL2011001232A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
UY32037A (es) Daa-piridina
AR077333A1 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina -2 humana
CL2009000447A1 (es) Compuestos derivados de (1h-pirrolo{2,3-b}piridin-5-il)-sulfonamido-benzamida sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento del cancer, a travez de la inhibicion de raf.
ECSP099225A (es) Compuestos antagonistas del receptor de glucagón, composiciones que contienen dichos compuestos y procedimientos de uso
CL2007003423A1 (es) Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda
CL2011001331A1 (es) Clorhidrato de nalmefeno dihidratado; métodos para su preparación; composición farmacéutica que lo comprende; y uso para el tratamiento del alcoholismo.
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
AR083395A1 (es) Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico
AR075982A1 (es) Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion